Breaking News Instant updates and real-time market news.

FATE

Fate Therapeutics

$9.97

-0.54 (-5.14%)

06:48
04/06/18
04/06
06:48
04/06/18
06:48

Fate Therapeutics approach validated by MD Anderson data, says Wells Fargo

Wells Fargo analyst Jim Birchenough reiterates an Outperform rating on Fate Therapeutics with an $18 price target following review of the initial clinical results from an "off-the-shelf" NK-cell therapeutic from MD Anderson. The results validate Fate's own platform of NK-cell therapeutics, including off-the-shelf induced pluripotent stem cell derived FATE-NFT500 and engineered NK-CAR candidates like FATE-FT519 targeting CD19, Birchenough tells investors in a research note. He notes that MD Anderson presented a clinical update from a first-inpatient phase 1/2 trial of a cord blood derived natural killer cell CD19 chimeric antigen receptor.

FATE Fate Therapeutics
$9.97

-0.54 (-5.14%)

03/06/18
03/06/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Spectra Energy Partners (SEP) downgraded to Hold from Buy at Stifel with analyst Selman Akyol saying he believes the company's cash flow growth will be on the low end relative to its large cap peers. 2. GrubHub (GRUB) downgraded to Neutral from Buy at BofA/Merrill with analyst Nat Schindler. citing valuation. 3. Canadian National (CNI) downgraded to Underperform from Neutral at BofA/Merrill with analyst Ken Hoexter saying CEO Luc Jabin stepped down at a time when the company's pace of growth is set to stagnate as rising costs to maintain service levels offset volume and pricing gains. 4. General Mills (GIS) downgraded to Hold from Buy at Gabelli. 5. Fate Therapeutics (FATE) was downgraded to Market Perform from Outperform at Raymond James and to Neutral from Buy at H.C. Wainwright. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/15/18
PIPR
03/15/18
NO CHANGE
Target $20
PIPR
Overweight
Fate Therapeutics remains a 2018 top pick at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff says Fate Therapeutics remains a 2018 top pick for off-the-shelf Natural Killer cell therapy with clinical data and pipeline expansion this year. With Phase I ovarian cancer data this month, the analyst reiterates an Overweight rating on the shares with a $20 price target.
03/29/18
PIPR
03/29/18
NO CHANGE
Target $20
PIPR
Overweight
Fate Therapeutics Phase I data on NK100 'highly' encouraging, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff said he was "highly encouraged" by the preliminary safety and efficacy data from a Phase I trial on Fate Therapeutics' NK100 in two ovarian cancer patients that was presented at a medical summit. The first patient progressed and the second had stable disease at 28 days with early signs of tumor regression, he noted. Tenthoff said Fate remains a 2018 top pick and reiterated his Overweight rating and $20 price target on the shares.
03/29/18
HCWC
03/29/18
NO CHANGE
HCWC
Fate Therapeutics initial data for FATE-NK100 encouraging, says H.C. Wainwright
H.C. Wainwright analyst Edward White reiterated a Hold rating and $12 price target on Fate Therapeutics, noting the initial clinical data for FATE-NK100 that was announced earlier Thursday is encouraging, and saying the Hold rating is a reflection of the current stock price and not a "diminished outlook" for FATE-NK100.

TODAY'S FREE FLY STORIES

GOOG

Alphabet

$1,072.25

-2.17 (-0.20%)

, GOOGL

Alphabet Class A

$1,075.28

-4.12 (-0.38%)

06:02
04/19/18
04/19
06:02
04/19/18
06:02
Periodicals
Google Pay surpasses 100M downloads on Play Store, Android Police says »

Google Pay, called…

GOOG

Alphabet

$1,072.25

-2.17 (-0.20%)

GOOGL

Alphabet Class A

$1,075.28

-4.12 (-0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    Apr

INTC

Intel

$53.61

0.08 (0.15%)

06:01
04/19/18
04/19
06:01
04/19/18
06:01
Periodicals
Intel plans to shut down New Devices Group, The Information reports »

Intel plans to shut down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADMS

Adamas Pharmaceuticals

$25.86

0.86 (3.44%)

05:59
04/19/18
04/19
05:59
04/19/18
05:59
Hot Stocks
Adamas Pharmaceuticals announces final results from GOCOVRI Phase 3 study »

Adamas Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Apr

  • 25

    Apr

  • 25

    Apr

  • 12

    Jun

TSLA

Tesla

$293.42

5.8 (2.02%)

05:55
04/19/18
04/19
05:55
04/19/18
05:55
Hot Stocks
Tesla batteries delivering power at 662 locations in Puerto Rico, Musk says »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$109.31

-0.9 (-0.82%)

05:55
04/19/18
04/19
05:55
04/19/18
05:55
Hot Stocks
JPMorgan Chase announces branch expansion in Greater Washington DC »

JPMorgan Chase announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

  • 30

    May

  • 13

    Jul

  • 12

    Oct

ICLK

iClick Interactive Asia

$7.76

0.19 (2.51%)

05:55
04/19/18
04/19
05:55
04/19/18
05:55
Conference/Events
iClick Interactive Asia management to meet with Roth Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Apr

  • 20

    Apr

SBNY

Signature Bank

$135.08

-1.99 (-1.45%)

05:52
04/19/18
04/19
05:52
04/19/18
05:52
Hot Stocks
Signature Bank reports Q1 EPS ex-items $2.69, consensus $2.67 »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Apr

  • 25

    Apr

SCCO

Southern Copper

$57.33

0.745 (1.32%)

05:50
04/19/18
04/19
05:50
04/19/18
05:50
Downgrade
Southern Copper rating change  »

Southern Copper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

FOXA

21st Century Fox

$37.32

-0.22 (-0.59%)

, DIS

Disney

$101.21

-1 (-0.98%)

05:49
04/19/18
04/19
05:49
04/19/18
05:49
Hot Stocks
21st Century Fox rejected rival bid of $34.41 per share for assets »

Disney (DIS) disclosed…

FOXA

21st Century Fox

$37.32

-0.22 (-0.59%)

DIS

Disney

$101.21

-1 (-0.98%)

CMCSA

Comcast

$33.28

0.02 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 08

    May

  • 09

    May

NTRS

Northern Trust

$106.38

-0.04 (-0.04%)

05:47
04/19/18
04/19
05:47
04/19/18
05:47
Hot Stocks
Northern Trust enters partnership with The Northern Pool »

The Northern Pool has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$81.72

-0.09 (-0.11%)

, AMGN

Amgen

$175.14

0.19 (0.11%)

05:36
04/19/18
04/19
05:36
04/19/18
05:36
Hot Stocks
Novartis appoints John Tsai as Chief Medical Officer, Head of GDD »

Novartis (NVS) announced…

NVS

Novartis

$81.72

-0.09 (-0.11%)

AMGN

Amgen

$175.14

0.19 (0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 24

    Apr

  • 30

    Apr

  • 17

    May

  • 21

    May

  • 28

    May

  • 05

    Jun

AMZN

Amazon.com

$1,527.24

23.92 (1.59%)

05:36
04/19/18
04/19
05:36
04/19/18
05:36
Recommendations
Amazon.com analyst commentary  »

Amazon online retail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

NVS

Novartis

$81.72

-0.09 (-0.11%)

05:34
04/19/18
04/19
05:34
04/19/18
05:34
Earnings
Novartis confirms FY18 revenue guidance of growth of low to mid single-digit »

Novartis noted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 17

    May

  • 21

    May

  • 05

    Jun

NVS

Novartis

$81.72

-0.09 (-0.11%)

05:34
04/19/18
04/19
05:34
04/19/18
05:34
Hot Stocks
Novartis reports Q1 Alcon sales of $1.8B »

Alcon net sales were…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 17

    May

  • 21

    May

  • 05

    Jun

RDN

Radian Group

$15.36

-0.91 (-5.59%)

05:30
04/19/18
04/19
05:30
04/19/18
05:30
Recommendations
Radian Group analyst commentary  »

Radian Group price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

NVS

Novartis

$81.72

-0.09 (-0.11%)

05:29
04/19/18
04/19
05:29
04/19/18
05:29
Hot Stocks
Novartis Q1 results continue to demonstrate benefit from turnaround plan actions »

Novartis noted, Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 17

    May

  • 21

    May

  • 05

    Jun

MTG

MGIC Investment

$10.50

-0.275 (-2.55%)

05:29
04/19/18
04/19
05:29
04/19/18
05:29
Downgrade
MGIC Investment rating change  »

MGIC Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESNT

Essent Group

$34.83

-2.045 (-5.55%)

, MTG

MGIC Investment

$10.50

-0.275 (-2.55%)

05:28
04/19/18
04/19
05:28
04/19/18
05:28
Downgrade
Essent Group, MGIC Investment, Radian Group rating change  »

Essent Group downgraded…

ESNT

Essent Group

$34.83

-2.045 (-5.55%)

MTG

MGIC Investment

$10.50

-0.275 (-2.55%)

RDN

Radian Group

$15.36

-0.91 (-5.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 04

    May

NVS

Novartis

$81.72

-0.09 (-0.11%)

05:27
04/19/18
04/19
05:27
04/19/18
05:27
Hot Stocks
Novartis reports Q1 Sandoz net sales of $2.5B »

Sandoz net sales were…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 17

    May

  • 21

    May

  • 05

    Jun

NVS

Novartis

$81.72

-0.09 (-0.11%)

05:25
04/19/18
04/19
05:25
04/19/18
05:25
Earnings
Novartis reports Q1 core EPS $1.28, consensus $1.29 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 17

    May

  • 21

    May

  • 05

    Jun

PG

Procter & Gamble

$78.19

-0.23 (-0.29%)

, TEVA

Teva

$17.91

0.065 (0.36%)

05:23
04/19/18
04/19
05:23
04/19/18
05:23
Hot Stocks
Procter & Gamble acquires Consumer Health business of Merck KGaA for EUR 3.4B »

Procter & Gamble (PG)…

PG

Procter & Gamble

$78.19

-0.23 (-0.29%)

TEVA

Teva

$17.91

0.065 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 27

    Apr

  • 18

    May

  • 05

    Jun

  • 16

    Jun

GOL

GOL Linhas

$13.51

0.72 (5.63%)

05:22
04/19/18
04/19
05:22
04/19/18
05:22
Downgrade
GOL Linhas rating change  »

GOL Linhas downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$78.19

-0.23 (-0.29%)

05:22
04/19/18
04/19
05:22
04/19/18
05:22
Hot Stocks
Breaking Hot Stocks news story on Procter & Gamble »

Procter & Gamble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 27

    Apr

LN

Line Corp.

$38.30

0.09 (0.24%)

05:20
04/19/18
04/19
05:20
04/19/18
05:20
Downgrade
Line Corp. rating change  »

Line Corp. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$177.84

-0.41 (-0.23%)

05:16
04/19/18
04/19
05:16
04/19/18
05:16
Recommendations
Apple analyst commentary  »

Mizuho sees risk to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.